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Abstract 
SET, the translocation breakpoint-encoded protein in acute undifferentiated leukemia (AUL), is identified as a 39-kDa phosphoprotein found 
predominantly in the cell nuclei [1994, J. Biol. Chem. 269,2258-22621. SET is fused to a putative oncoprotein, CAN, in AUL and is thought o regulate 
the transformation potential of SET-CAN by its nuclear localization and phosphorylation. We investigated in detail the in vivo phosphorylation of 
SET. Phosphorylation of SET occurred in all human cell lines examined in vivo, primarily on serine residues. Endoproteinase Glu-C digestion of 
phosphorylated SET yielded two phosphopeptides. By radiosequencing, we identified the in vivo phosphorylation sites of SET as Se? and Se?‘. The 
surrounding sequences of Ser’ and Se?’ contained an apparent consensus ite sequence for protein kinase C. 
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I. Introduction 
The chromosomal translocation (6;9) (p23;q34) in 
acute nonlymphocytic leukemia resulted in the forma- 
tion of a dek-can fusion gene [l]. In a case of acute 
undifferentiated leukemia (AUL), the putative oncogene 
can was fused to a different cellular gene, named sef, and 
is assumed to have been activated [2]. SET protein en- 
coded by the set gene was recently biochemically identi- 
fied [3]. Characterization of SET revealed that it is a 
39-kDa phosphoprotein found predominantly in the cell 
nuclei and is expressed ubiquitously in various human 
cell lines. Analogous to acidic domains in NAP-l, HMG- 
1, HMG-2, B-23, nucleolin, GAL4, and VP16 [4-lo], the 
acidic motif of SET is thought to serve as a nucleosomel 
chromatin assembly domain or a transcription activation 
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domain [2,3]. It is known that the variable phosphoryla- 
tion of nuclear proteins has functional consequences for 
the regulation of gene expression, replication, chromatin 
conformation, and nuclear transport by protein-protein 
and protein-DNA/RNA interactions and constitutes 
one mechanism by which nuclear events are modulated 
by external stimuli [l l-201. Similarly, the phosphoryla- 
tion of SET may be involved in the regulation of SET 
function(s) in the nuclei and the transformation potential 
of SET-CAN in AUL. However, little is known about 
the phosphorylation of SET. 
We were therefore interested in investigating in detail 
the phosphorylation of SET. For this purpose, we iso- 
lated 32P-labeled SET from various human cell lines by 
metabolic labeling and immunoprecipitation, and deter- 
mined in vivo phosphorylation sites within the SET mol- 
ecule by radiosequencing. Our findings should be helpful 
in studying the function of SET and chimeric SET-CAN 
proteins in the mechanism of AUL leukemogenesis. 
2. Materials and methods 
2.1. Cells and metabolic labeling 
HUT-102, MT-2, and TL-Su [21] are human T-cell lines infected with 
human T-cell leukemia virus type I (HTLV-I). HUT-78 [22], H-9 [23], 
and Jurkat [7] are uninfected human T-cell lines. Raji [21] is a human 
B-cell line. K-562 [24] and HL-60 [24] are human cell lines derived from 
erythroleukemia nd promyelocytic cells, respectively. HOS [7] and 
HeLa [7] are human cell lines derived from osteogenic sarcoma and 
epitheloid carcinoma, respectively. Hematopoietic ell lines were rou- 
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tinely maintained in RPM1 1640 medium supplemented with 10% fetal 
calf serum at 37°C in humidified air with 5% COz. Cell lines HOS and 
HeLa were grown in Dulbecco’s modified Eagle’s medium supple- 
mented with 10% fetal calf serum. Metabolic labeling of cells with 
[“Plorthophosphate (18.5 MBq/ml, >315 TBq/mmol) was conducted 
by incubating cells (1 x lo6 cells/ml) m phosphate-free medium supple- 
mented with 10% fetal calf serum dialyzed against Tris-buffered saline 
(20 mM Tris-HCl (pH 7.5). 0.15 M NaCl) at 37’C for 2 h as previously 
described [25,26]. 
2.2. Peptlde synthesis and antibody preparation 
Oligopeptides were synthesized with an automated peptide synthe- 
sizer (Applied Biosystems model 430A) using t-butoxycarbonyl amino 
acids and p-methylbenzhydrylamine resins or using 9-fluoren- 
ylmethoxycarbonyl amino acids and PAL supports (Millipore) as 
described previously [7,26]. The synthetic peptide AQAAKVSKKEL- 
NSNC (residues 3-16 of SET) was conjugated to keyhole limpet hemo- 
cyanin through the cysteine handle with the bifunctional reagent 
m-maleimidobenzoyl-Nhydroxysuccimmide ester (Pierce). Antiserum 
against he conjugated peptide was raised in rabbits. An immunoglob- 
ulin G (IgG) fraction of antiserum was prepared as described previously 
[15,24] and used in this study. 
2.3. Immunoprecipitation and gel electrophoresis 
Metabolically labeled cells were lysed with RIPA buffer (50 mM 
Tris-HCI (pH 7.5), 0.15 M NaCl, 4 mM EDTA, 1% Nonidet P-40,0.1 % 
sodium debxycholate, 10 mM Na4P,0,, 10 mM NaF, 2 mM Na3V0,, 
1 mM ohenvlmethvlsulfonvl fluoride) at 4°C for 30 min. After centrif- 
ugatioi at iS,OOO~rpm (Ebpendorf ‘microcentrifuge) for 10 min, the 
supernatant was incubated with anti-SET serum at 4°C for 2 h. The 
immunocomplexes were precipitated with protein A-Sepharose CL-4B, 
then extensively washed with RIPA buffer and LSW buffer (10 mM 
Tns-HCI (pH 7.6), IO mM NaCl) as described previously [15,17,25,26]. 
The immunoprecipitates were subjected to SDS-PAGE on 8-16% gra- 
dient polyacrylamlde gels according to the procedure of Laemmli [27]. 
After electrophoresis, gels were stained with Coomassie brilliant blue 
R-250, dried, and subjected to autoradiography. 
2.4. Phosphoamino acid analysis 
32P-labeled SET was transferred to an Immobilon PVDF membrane 
(Millipore) and hydrolyzed in 6 N HCl vapor at 110°C for 2 h. The 
resulting phosphoamino acid samples were mixed with standards 
(phosphoserine, phosphothreonine, and phosphotyrosine; 5pg each) 
and applied onto cellulose-coated thin-layer glass plates (20 x 20 cm). 
High-voltage lectrophoresis was performed in pH 3.5 buffer (pyridme/ 
acetic acid/water; 1: 10:189, by volume) at 4 “C. ‘*P-labeled phospho- 
amino acids were identified by autoradiography, and phosphoamino 
acid standards were identified by spraying the plates with ninhydrin 
[25.26]. 
2.5. Endoproteinase digestion and HPLC separation 
Endoproteinase Glu-C and TPCK-trypsin were used for digestion of 
32P-labeled SET, sequentially. Digestions were carried out at 37°C in 
50 mM NH,HCO, (pH 7.8) for 4 h followed by overnight incubation 
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with a second identical dose of proteinase. The samples after each 
digestion were subjected to reversed-phase HPLC using a C,, column 
(0.46 x 30 cm, Waters) on an LKB HPLC system as previously de- 
scribed [26]. The elution was performed by a linear gradient of 040% 
solvent B for 120 min (solvent A: 0.05% trifluoroacetic acid m water; 
solvent B: 0.05% trifluoroacetic acid in acetonitnle). 
2.6. Radiosequencmg 
Each phosphopeptide from reversed-phase HPLC was subjected to 
sequential Edman degradation in a Beckman 890C automated spinning 
cup sequenator with 10 nmol of horse apomyoglobin (Sigma) carrier 
as described previously [26]. Fractions collected at each cycle of sequen- 
tial analysis were transferred to scintillation vials, dried with NZ and 
heat, redissolved in 8 ml of Aquasure (DuPont-New England Nuclear). 
and allowed to equilibrate in the dark for 2 h, and scintillation counted. 
3. Results 
3.1. In vivo phosphorylation of SET 
The SET protein encoded by the set gene open reading 
frame consists of 277 amino acids and has a molecular 
mass of 39 kDa. A number of various human cell lines 
express nearly the same level of SET, as recently reported 
[3]. To examine whether the in vivo phosphorylation of 
SET occurs ubiquitously, we subjected various human 
cell lines (HUT-102, HUT-78, MT-2, H-9, TL-Su, Jur- 
kat, Raji, K-562, HL-60, HOS, and HeLa) to metabolic 
labeling with [32P]orthophosphate followed by im- 
munoprecipitation. As shown in Fig. I, 32P-labeled SET 
was immunoprecipitated in all cell lines tested. The in- 
corporation of 32P, into SET showed a marked variation 
depending upon the cell line. Since the radioactivity asso- 
ciated with SET was highly sensitive to alkaline phos- 
phatase treatment (data not shown) [3], incorporation of 
the radioactivity was due to protein phosphorylation, 
but not to ADP-ribosylation. 
3.2. Phosphoamino acid analysis of phosphorylated SET 
To identify the phosphorylated amino acids present in 
SET, 32P-labeled SET from various human cell lines were 
transferred from the gel onto PVDF membrane and sub- 
jected to partial acid hydrolysis in 6 N HCI vapor at 
110°C for 2 h. Phosphoamino acids were separated by 
Fig. 1. In vivo phosphorylation of SET. Cells (2 x 106) were metabolically labeled with [32P]orthophosphate for 2 h at 37°C. lysed, and subjected 
to immunoprecipitation with anti-SET IgG (even-numbered lanes) and preimmune IgG (odd-numbered lanes) as described in Section 2. The cell lines 
examined were HUT-102 (lanes 1 and 2), HUT-78 (lanes 3 and 4), MT-2 (lanes 5 and 6), H-9 (lanes 7 and 8), TL-Su (lanes 9 and 10). Jurkat (lanes 
11 and 12). Raji (lanes 13 and 14), K-562 (lanes 15 and 16). HL-60 (lanes 17 and 18). HOS (lanes 19 and 20), and HeLa (lanes 21 and 22). 
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Fig. 2. Phosphor&no acid analysis of SET. 32P-labeled SET from various human cell lines was immunoprecipitated, eluted from gels, and hydrolyzed 
in 6 N HCl vapor at 1 10°C for 2 h. Phosphoamino acids were separated by high-voltage lectrophoresis and subjected to autoradiography. SET 
proteins were isolated from lane 1, HUT-102; lane 2, HUT-78 lane 3, MT-2; lane 4, H-9; lane 5, TL-Su; lane 6, Jurkat; lane 7, Raji; lane 8, K-562; 
lane 9, HL-60; lane 10, HOS; lane 11, HeLa. The positions of unlabeled phosphoserine (P-Ser), phosphothreonine (P-Thr), and phosphotyrosine 
t P-Tyr) are shown by broken circles. 
high-voltage electrophoresis and detected by autoradi- 
ography. As shown in Fig. 2, in all cell lines tested, SET 
was phosphorylated mainly on serine residue(s) in vivo. 
Phosphothreonine and phosphotyrosine were not detect- 
able in any of the cells examined. 
3.3. Identljkation of in vivo phosphorylation sites of SET 
To determine the precise location of the phosphor- 
ylated serine(s), we prepared 32P-labeled SET by meta- 
bolic labeling followed by immunoprecipitation. After 
extensive digestion with endoproteinase Glu-C, the re- 
sulting peptides were separated by C,* reversed-phase 
HPLC (Fig. 3). Three peaks of 32P-radioactivity were 
isolated. Peak 1 contained 32P,. Each 32P-labeled 
phosphopeptide from peaks 2 and 3 was mixed with 
myoglobin as carrier protein and subjected to automated 
Edman degradation in a spinning cup sequenator. Suc- 
cessive degradation and the sequence cycle number were 
Fraction Number 
Fig. 3. Isolation of endoproteinase Glu-C-digested phospho-peptides 
by C,* reversed-phase HPLC. ‘*P-Labeled SET was prepared by im- 
munoprecipitation and SDS-PAGE, then digested with endoproteinase 
Glu-C. The resulting peptides were applied onto a C,, column 
(0.46 x 30 cm). The phosphopeptides were separated at a flow rate of 
1.0 ml/ fractiommin with a linear gradient of o-40% acetonitrile in 
0.05% trifluoroacetic acid as shown by the dashed line. The radioactiv- 
ity in each fraction was monitored by Cerenkov counting. 
monitored by analysis of phenylthiohydantoin amino 
acids of carrier protein released at cycles 2 and 11. The 
amount of radioactivity released during each cycle was 
monitored by scintillation counting to determine the po- 
sition(s) of phosphorylated amino acids relative to the N 
terminus of the peptides (Fig. 4). 32P-radioactivity was 
released at the second cycle of peak 2 (Fig. 4A). Only one 
predicted Glu-C peptide (residues 23-25) contained a 
serine in this position. In contrast, no released radioac- 
tivity was observed during 24 cycles in peak 3 (Fig. 4B). 
This result indicated that the N terminus of this Glu-C 
peptide was blocked by posttranslational modification 
such as acetylation and this peptide corresponded to the 
N-terminal residues 1-12 of SET. 
- 
5 10 15 20 2 
Cycle 
Fig. 4. Radiosequence analysis. Each Glu-C-digested phosphopeptide 
from reversed-phase HPLC was subjected to automated Edman degra- 
dation. The amounts of “P radioactivity released uring each cycle are 
shown. (A) Peak 2 in Fig. 3; (B) Peak 3 in the same figure. 
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Fig. 5. Analysis of N-terminal Glu-C peptide by tryptic digestion and 
radiosequencing. (A) Phosphorylated N-terminal Glu-C peptide corre- 
sponding to peak 3 in Fig. 3. (B) The phosphopeptide was digested with 
TPCK-trypsin. The resulting tryptic peptides were separated by C,, 
reversed-phase HPLC as described in Fig. 3. (C) The phosphopeptide 
isolated in panel B was subjected to radiosequencing. 
To identify the phosphorylation site(s) in the N-termi- 
nal Glu-C peptide (Figs. 3 and 5A), we subjected this 
peptide to a secondary digestion with TPCK-trypsin fol- 
lowed by HPLC and radiosequencing. After extensive 
tryptic digestion, a peak of 32P-radioactivity was detected 
in the 0.67% acetonitrile fraction of C,* reversed-phase 
I 
peak 3 
I 
HPLC (Fig. 5B). This elution position indicated that the 
resulting phosphopeptide was highly hydrophilic and 
corresponded to VS*K (residues 8-10) rather than 
MS*AQAAK (residues l-7). This result was also sup- 
ported by relative retention times on the same reversed- 
phase HPLC column of the synthetic peptides AcM- 
SAQAAKVSKKE, AcMSAQAAK, and VSK (data not 
shown). Finally, 32P-labeled peptide in Fig. 5B was sub- 
jected to automated Edman degradation followed by 
scintillation counting. 32P-radioactivity was released at 
the second cycle (Fig. 5C). This position corresponded 
to Ser’. Similar analyses with chymotryptic digestion fol- 
lowed by HPLC and radiosequencing also revealed the 
same results (data not shown). Thus, Ser’ and SerZ4 were 
identified as in vivo phosphorylation sites of SET (Fig. 
6). Moreover, the surrounding sequences of Ser’ and 
Ser24 coincide with the consensus equence of phospho- 
rylation sites of protein kinase C. 
4. Discussion 
In this report, we examined in detail the in vivo phos- 
phorylation of SET. Phosphorylation of SET was ob- 
served in all human cell lines tested (HUT-102, HUT-78, 
MT-2, H-9, TL-Su, Jurkat, Raji, K-562, HL-60, HOS, 
and HeLa), although the level of phosphorylation varied 
depending upon the cell line (Fig. 1). The in vivo phos- 
phorylation of SET therefore occurs in various types of 
cells ubiquitously. In every case, the major phospho- 
amino acid of phosphorylated SET was phosphoserine, 
indicating that SET is a substrate for one or more cellu- 
lar serine/threonine kinases. Tyrosine kinases are not 
involved, since phosphotyrosine was not detected. 
By analysis of radiosequencing data, we identified in 
vivo phosphorylation sites of SET as Ser’ and SerZ4 
(Figs. 3-6). The surrounding sequences of Ser’ and Ser24 
contain an apparent consensus ite sequence for protein 
kinase C, Ser*-X-Arg/Lys [28]. A wide range of in vivo 
protein kinase C substrate proteins including nuclear 
regulatory proteins has been reported [ll]. Hence, it is 
possible that protein kinase C may utilize the suitable 
substrate sequences on SET and phosphorylate SET in 
response to physiological stimuli. 
Although the function(s) of SET is not known, SET 
is essential in the mechanism of leukemogenesis in AUL, 
particularly by activating the putative oncoprotein, 
CAN, in nuclei and stimulating the transformation po- 
peak 2 
II I I 
‘m-s-A-q-*-*-K-“-~-K K-E-L-N-S-N-H-D-G-A-D-E-T-S_E-T-S~-K-t+Q-Q-E-A-I-E- t*tt t t 
1 t-4-C 20 ----t 30 
Fig. 6. In vivo phosphorylation sites of SET. Arrows mark the predicted sites of Glu-C (upper) and tryptic (lower) cleavage. Brackets indicate 
Glu-C-digested phosphopeptides, identified by the numbering system of Fig. 3. Asterisks indicate residues phosphorylated in vivo. The consensus 
sequences of the sites phosphorylated by PK-C are marked with wavy underlines. 
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tential of SET-CAN fusion protein [2,3]. It is known that 
many nuclear proteins, including proteins thought to be 
involved in gene expression, replication, chromatin con- 
formation, and nuclear transport (e.g. CREB, c-Fos, c- 
Jun, ~53, histone, B-23, and HTLV-I Rex), are also 
phosphorylated in vivo in response to physiological stim- 
uli and their activities are regulated by phosphorylation 
[l l-201. By analogy with these nuclear regulatory pro- 
teins, the in vivo phosphorylation of SET at Ser’ and 
Se?4 in nuclei may play a key role for its function by 
changing structural conformation or affinity for protein- 
protein or protein-DNA/RNA interaction. The findings 
described in this report should be helpful in further stud- 
ying the function of SET and chimeric SET-CAN pro- 
teins in the mechanism of leukemogenesis n AUL. 
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